ATE:CA:TSX-Antibe Therapeutics Inc. (CAD)

COMMON STOCK | Medical Devices | TSX

Last Closing Price

CAD 0.93

Change

-0.04 (-4.12)%

Market Cap

CAD 0.05B

Volume

0.49M

Avg Analyst Target

CAD 4.31 (+363.90%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Antibe Therapeutics Inc., a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada. Address: 15 Prince Arthur Avenue, Toronto, ON, Canada, M5R 1B2

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PRN:CA Profound Medical Corp

-0.65 (-3.52%)

CAD0.38B 74.00 N/A
VMD:CA Viemed Healthcare Inc

-0.14 (-1.96%)

CAD0.28B 21.12 10.00
TMD:CA Titan Medical Inc

-0.03 (-1.60%)

CAD0.21B 7.09 680.83
NVCN:CA Neovasc Inc

+0.04 (+4.71%)

CAD0.06B 0.12 0.36
HSM:CA Helius Medical Technologies In..

N/A

CAD0.04B N/A N/A

ETFs Containing ATE:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -76.34% 20% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.34% 20% F N/A N/A
Trailing 12 Months  
Capital Gain -73.80% 20% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.80% 20% F 1% F
Trailing 5 Years  
Capital Gain -45.29% 75% C 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.29% 75% C 12% F
Average Annual (5 Year Horizon)  
Capital Gain 50.28% 80% B- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.28% 80% B- 75% C
Risk Return Profile  
Volatility (Standard Deviation) 98.20% 60% D- 8% F
Risk Adjusted Return 51.20% 60% D- 56% F
Market Capitalization 0.05B 20% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.81 80% B- 85% B
Price / Cash Flow Ratio -462.19 100% A+ 99% A+
EV/EBITDA 0.34 100% A+ 99% A+
Management Effectiveness  
Return on Equity -51.01% 60% D- 9% F
Return on Invested Capital -86.25% 40% F 3% F
Return on Assets -22.94% 40% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.60 100% A+ 65% D
Short Percent 0.11% 80% B- 81% B-
Beta -0.07 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector